Imatinib reverses doxorubicin resistance by inhibiting cell survival.

<p>Caspase-3/7 activity (<b>A,B,E</b>), Annexin V staining (<b>C</b>), or PARP cleavage (<b>D,F</b>) were assessed in lysates from attached and detached treated cells (40 h unless otherwise indicated). Mean±SEM of 3 experiments (<b>A,B,E</b>) or representative of 3 independent experiments (<b>C,D,F</b>). Some error bars (A,B,E) are too small to visualize. *p<0.05, **<i>p</i>≤0.01, ***<i>p</i><0.001 (see methods).